Physician profile
Jon Harrell Docherty
NPI 1336185057
$15,482.10
in general payments reported to CMS, 2019-2025
30 companies · $3,330 in 2025
The $3,330 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $963 · 2021: $1,157 · 2022: $3,143 · 2023: $2,798 · 2024: $2,858 · 2025: $3,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,831 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,831.16 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,928.74 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,106.56 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Astrazeneca Pharmaceuticals LP | $1,677.47 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| Amgen INC. | $1,242.10 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $1,083.80 | 2019-2025 | Benlysta |
| Pfizer INC. | $962.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $743.81 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $736.54 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $564.06 | 2020-2025 | Acthar |
| Lilly USA, LLC | $546.68 | 2019-2025 | Taltz |
| Ucb, INC. | $535.51 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.73 | 2020-2025 | Ofev, Spevigo, Cyltezo |
| Sandoz INC. | $353.97 | 2023-2025 | Hyrimoz, Jubbonti |
| Forte Bio-Pharma LLC | $321.57 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Regeneron Healthcare Solutions, INC. | $235.41 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $188.64 | 2020-2025 | |
| Tersera Therapeutics LLC | $170.89 | 2022-2023 | Quzyttir |
| Ani Pharmaceuticals, INC. | $158.89 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $138.45 | 2020-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $117.67 | 2019-2024 | Orencia |
| Radius Health, INC. | $59.32 | 2019-2025 | Tymlos |
| Ultragenyx Pharmaceutical INC. | $55.30 | 2023 | |
| Mallinckrodt Enterprises LLC | $42.38 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $33.94 | 2024 | Arcalyst |
| Sobi, INC | $28.87 | 2025 | |
| Amarin Pharma, INC. | $27.78 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $15.62 | 2025 | |
| Medtronic, INC. | $15.34 | 2025 | Intellis Adaptivestim |
| Tonix Medicines, INC. | $15.03 | 2025 | Tonmya |
| Hikma Pharmaceuticals USA | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Docherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.